Last reviewed · How we verify
NCT05819242
The Reliability And Validity Of A Smartphone App
trial testing Angulus in Rheumatoid Arthritis in 64 participants. Completed in 5 October 2023.
5 October 2023
Quick facts
| Lead sponsor | Kirsehir Ahi Evran Universitesi |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 7 April 2023 |
| Primary completion | 5 October 2023 |
| Estimated completion | 5 October 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Angulus
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
- Carpal Tunnel Syndrome — all drugs for Carpal Tunnel Syndrome →
Sponsor
Kirsehir Ahi Evran Universitesi — full company profile →
Who can join
Adults 18 to 65, any sex, with Rheumatoid Arthritis or Carpal Tunnel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to validate a smartphone app called Angulus. The main question it aims to answer is: • Is an Angulus App valid and reliable system for masuring hand and wrist range of motion? Participants will be evaluated by goniometers which is a gold standart for range of motion assessment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05819242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Angulus
Trials testing the same drug.
- NCT03496220 — Effect of Angulus on Patient-elevation Compliance · NA · completed
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Kirsehir Ahi Evran Universitesi trials
Trials by the same sponsor.
- NCT07506915 — The Effect of Cognitive Behavioral Therapy · NA · enrolling by invitation
- NCT07502248 — PENG Block With or Without PPD Block for Postoperative Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
- NCT07438392 — Tecar Therapy in Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07450742 — Digital Storytelling and Mother's Knowledge and Attitudes Towards Newborn Screning · NA · not yet recruiting
- NCT07414017 — Comparison of Focus of Attention in Virtual Reality-Based Exercise Training in Older Adults With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05819242 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kirsehir Ahi Evran Universitesi
- Last refreshed: 6 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05819242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing